Key result
Moderate or severe PPM after TAVI is not associated with worse functional or quality-of-life improvements.
Why the study?
While patient-prosthesis mismatch after TAVI has not been associated with increased mortality, its impact on quality of life remains unclear.
Does moderate or severe predicted or measured patient-prosthesis mismatch impair quality of life and functional recovery at 30 days and 1 year in patients undergoing TAVI for severe native aortic stenosis?
Cohort (n=3,013)
Yes
Does moderate or severe predicted or measured patient-prosthesis mismatch impair quality of life and functional recovery at 30 days and 1 year in patients undergoing TAVI for severe native aortic stenosis?
Moderate or severe patient-prosthesis mismatch (whether predicted or measured) does not diminish 30-day or 1-year quality-of-life or functional recovery after TAVI, suggesting PPM risk alone need not drive aggressive procedural modifications.
Answers are grounded in this paper and cite their sources.
PPM after TAVI was not associated with inferior QoL or NYHA gains; leaves open whether valve selection should prioritize mismatch avoidance.
Background While patient-prosthesis mismatch (PPM) after transcatheter aortic valve implantation (TAVI) has not been associated with increased mortality, its impact on quality of life (QOL) remains unclear. Aims To evaluate the relationship between predicted (PPM P ) and measured (PPM M ) PPM and QoL, assessed using New York Heart Association (NYHA) class and Kansas City Cardiomyopathy Questionnaire (KCCQ) scores at 30 days and 1-year post-TAVI. Methods We retrospectively analyzed 3,013 patients undergoing TAVI (2012-2022) within a large healthcare system. Patients were stratified by effective orifice area indexed to body surface area (EOAi) into no (EOAi >0.85 cm 2 /m 2 ), moderate (EOAi >0.65 cm 2 /m 2 or ≤0.85 cm 2 /m 2 ), or severe (EOAi ≤0.65 cm 2 /m 2 ) PPM, with lower cut-offs for obese patients (BMI ≥ 30 kg/m 2 ). Results The median age was 80.0 [73.0;86.0] years, and 55.6% were female with a median Society of Thoracic Surgery risk score of 4.70% [2.66;7.64]. Overall, TAVI led to significant improvements in NYHA and KCCQ scores at 30 days and 1 year. Neither severe PPM P nor severe PPM M was associated with inferior QoL outcomes improvement (all p>0.05). Conclusion In this large cohort, TAVI yielded substantial and durable QoL gains, regardless of PPM severity or valve type. These findings suggest that moderate or severe PPM does not diminish functional recovery and should not be a primary determinant in valve selection or procedural strategy at 1-year.
No takes yet. Share an insight, caveat, or question.
Al‐Azizi et al. (2025) conducted a cohort in Severe native aortic stenosis undergoing transcatheter aortic valve implantation (TAVI) (n=3,013). Patient-prosthesis mismatch (predicted and measured moderate or severe PPM) vs. No patient-prosthesis mismatch (EOAi >0.85 cm2/m2, or >0.70 cm2/m2 if BMI >=30 kg/m2) was evaluated on Change in quality of life (Kansas City Cardiomyopathy Questionnaire [KCCQ] score and New York Heart Association [NYHA] functional class) from baseline to 30 days and 1 year (p=>0.05). Moderate or severe patient-prosthesis mismatch (predicted or measured) was not associated with inferior quality of life or NYHA functional improvements at 30 days or 1 year after TAVI.
Synapse has enriched 10 related papers. Consider them for comparative context: